pc
main
caus
death
follow
hsct
children
aim
evalu
earli
predictor
mortal
paediatr
recipi
pc
retrospect
observ
studi
patient
episod
pi
chest
radiographi
patient
undergon
hsct
tertiari
univers
hospit
januari
decemb
perform
followup
median
month
episod
led
death
aetiolog
diagnosi
made
noninvas
test
episod
ad
bronchoalveolar
lavag
andor
lung
biopsi
episod
diagnost
yield
p
thu
specif
diagnosi
obtain
episod
aetiolog
identif
treatment
modif
diagnosi
decreas
mortal
p
p
howev
number
organ
dysfunct
begin
pi
higher
mortal
group
compar
survivor
group
vs
p
hepat
dysfunct
ci
p
neutropaenia
ci
p
independ
associ
risk
mortal
therefor
hepat
dysfunct
neutropaenia
independ
earli
predictor
mortal
hsct
recipi
pc
contribut
deterior
patient
pc
investig
howev
previou
studi
report
factor
relat
pc
develop
focus
prevent
strategi
thu
studi
current
exist
regard
earli
predictor
respiratori
failur
death
associ
pc
hsct
therefor
aim
studi
evalu
abil
diagnost
workup
final
diagnos
treatment
modif
medic
condit
time
pc
initi
predict
mortal
hsct
recipi
children
januari
decemb
paediatr
patient
underw
hsct
hospit
initi
exclud
recipi
loss
graft
recipi
transfer
anoth
hospit
due
progress
underli
diseas
immedi
follow
stem
cell
infus
sixteen
patient
underw
second
hsct
plan
transplant
studi
period
case
consid
second
hsct
among
evalu
paediatr
patient
pc
investig
relaps
death
decemb
whichev
came
first
total
pi
episod
patient
retrospect
identifi
median
followup
period
month
iqr
final
includ
present
studi
studi
accord
helsinki
declar
institut
review
board
approv
obtain
studi
data
collect
regard
gener
characterist
includ
transplantrel
factor
clinic
find
outcom
pc
episod
gener
characterist
assess
includ
age
sex
underli
diseas
previou
lung
problem
number
type
hsct
stem
cell
sourc
engraft
day
human
leucocyt
antigen
compat
allograft
underli
diseas
categor
leukaemialymphoma
solid
tumour
nonmalign
diseas
includ
primari
immunodefici
aplast
anaemia
osteopetrosi
previou
lung
problem
identifi
patient
activ
lung
diseas
time
hsct
infus
neutrophil
engraft
day
defin
consecut
day
absolut
neutrophil
count
greater
equal
cellsl
pc
defin
new
develop
pi
chest
radiographi
simultan
respiratori
symptom
requir
admiss
evalu
treatment
respiratori
symptom
includ
cough
sputum
dyspnoea
chest
pain
blood
ting
sputum
cyanosi
pc
episod
time
diagnosi
transplant
diagnost
procedur
appli
time
bal
lb
sinc
pi
appear
relev
medic
condit
investig
addit
chang
empir
treatment
attribut
result
diagnost
test
record
evalu
medic
condit
time
pi
initi
consid
follow
presenc
engraft
syndrom
acut
gvhd
chronic
gvhd
vod
cmv
infect
medic
administr
organ
dysfunct
identifi
use
specif
pediatr
critic
care
medicin
criteria
publish
criteria
organ
dysfunct
cardiovascular
neurolog
haematolog
renal
gastrointestin
hepat
system
evalu
data
indic
sever
condit
within
hour
pi
appear
use
respiratori
dysfunct
exclud
criteria
arteri
blood
ga
frequent
measur
children
mild
respiratori
distress
acut
chronic
gvhd
assess
describ
elsewher
cmv
infect
defin
need
preemptiv
cur
induct
therapi
ganciclovir
preemptiv
treatment
start
halfdos
therapi
ganciclovir
cmv
antigenemia
assay
result
show
antigenexpress
polymorphonuclear
leucocyt
induct
therapi
start
result
show
antigen
express
polymorphonuclear
leucocyt
drug
alreadi
administ
note
follow
antibiot
antifung
agent
intraven
inject
inotrop
vasopressor
immunosuppress
includ
tacrolimu
cyclosporin
mycophenol
mofetil
steroid
prophylaxi
treatment
transplantationrel
complic
accord
analysi
accompani
medic
condit
earli
predictor
mortal
defin
statist
signific
comorbid
occur
pc
within
hour
pi
initi
outcom
episod
consid
term
number
admiss
picu
unexpect
event
cpr
unplan
transfer
picu
surviv
hospit
discharg
caus
death
clarifi
relat
pi
nonsurvivor
includ
patient
die
result
pc
reason
two
patient
die
classifi
survivor
group
die
due
recurr
underli
diseas
pi
evalu
use
noninvas
andor
invas
workup
noninvas
test
includ
blood
cultur
sputum
examin
serolog
test
chest
ct
scan
echocardiographi
pulmonari
function
test
sputum
collect
expector
use
nasopharyng
aspir
swab
transtrach
aspir
patient
alreadi
intub
sputum
gram
stain
cultur
bacteria
viru
fungi
subject
pcr
virus
mycoplasma
pneumonia
addit
acidfast
bacillu
stain
sputum
cultur
perform
high
suspicion
mycobacterium
tuberculosi
infect
exist
serolog
test
cmv
antigen
test
viral
load
aspergillu
antigen
test
mycoplasma
antibodi
assess
invas
test
bal
lb
arrang
base
joint
discuss
oncologist
pulmonologist
intensivist
radiologist
bal
perform
paediatr
pulmonologist
use
ageadjust
flexibl
bronchoscop
steril
normal
salin
instil
aliquot
ml
suction
sent
patholog
microbiolog
evalu
vat
lb
perform
paediatr
thorac
surgeon
ultrasoundguid
lb
perform
paediatr
radiologist
biopsi
bal
sampl
screen
infecti
pathogen
gram
acidfast
gomori
methenamin
silver
stain
viral
immunostain
sampl
also
process
bacteria
virus
fungi
cultur
pcr
mycobacterium
cmv
respiratori
viru
includ
respiratori
syncyti
viru
metapneumoviru
parainfluenza
influenza
rhinoviru
adenoviru
addit
perform
use
bal
fluid
immunofluoresc
assay
pcr
detect
pneumocysti
jiroveci
also
util
diagnos
base
clinic
radiolog
microbiolog
patholog
find
thoroughli
review
two
author
yhc
jdp
noninfecti
pc
follow
diagnos
confirm
ip
noncardiogen
pulmonari
oedema
andor
pleural
effus
perd
lung
gvhd
transfusionrel
acut
lung
injuri
ild
ip
defin
diffus
alveolar
damag
absenc
identifi
infecti
aetiolog
histolog
examin
ild
defin
similar
manner
ip
character
differ
injuri
site
clinic
featur
accord
recent
studi
perd
consid
presenc
fever
evid
pulmonari
injuri
form
hypoxia
spo
andor
infiltr
chest
radiograph
absenc
clinic
cardiac
dysfunct
diagnos
perd
symptom
andor
radiograph
find
occur
within
day
neutrophil
engraft
lung
gvhd
diagnos
primarili
presenc
obstruct
pulmonari
dysfunct
base
pulmonari
function
test
accompani
chest
ct
find
area
show
patchi
infiltr
bronchial
dilat
hypoattenu
increas
densiti
transfusionrel
acut
lung
injuri
identifi
whenev
patient
develop
hypoxem
respiratori
insuffici
shortli
transfus
blood
product
accord
outlin
diagnost
criteria
pulmonari
oedema
andor
pleural
effus
defin
presenc
characterist
infiltr
fluid
within
pleural
space
neg
cultur
benefici
respons
diuresi
without
cardiac
dysfunct
exclud
abovement
lung
problem
statist
analys
perform
use
spss
softwar
version
spss
inc
ibm
armonk
ny
usa
qualit
variabl
describ
number
continu
variabl
report
mean
median
iqr
gener
characterist
compar
survivor
nonsurvivor
via
chisquar
test
fisher
exact
test
categor
data
via
ttest
continu
data
logist
regress
perform
identifi
variabl
significantli
associ
poor
outcom
pi
episod
assess
estim
odd
ratio
confid
interv
ci
variabl
show
signific
univari
result
p
includ
multivari
logist
regress
multivari
model
construct
forward
stepwis
method
use
threshold
pvalu
remov
addit
model
surviv
estim
use
kaplanmei
method
differ
assess
use
logrank
test
gener
characterist
recipi
male
femal
one
pi
episod
follow
hsct
summar
tabl
use
noninvas
test
specif
aetiolog
discov
almost
half
pi
episod
episod
figur
among
two
episod
includ
addit
invas
test
show
use
inform
howev
episod
without
pathogen
discov
noninvas
test
given
aetiolog
diagnosi
ad
bal
andor
lb
result
diagnost
yield
p
final
vigor
diagnost
investig
infecti
caus
diagnos
episod
noninfecti
caus
diagnos
episod
howev
onethird
pc
identifi
episod
tabl
infecti
pc
viral
pneumonia
commonli
identifi
aetiolog
episod
one
three
patient
parainfluenza
viral
infect
experienc
tatma
time
among
noninfecti
pc
pulmonari
oedema
andor
pleural
effus
without
heart
dysfunct
lung
gvhd
found
episod
studi
patient
diagnos
cryptogen
organ
pneumonia
bronchiol
obliteran
syndrom
diffus
alveolar
haemorrhag
diagnost
workup
among
transplantationrel
complic
present
begin
pi
vod
higher
incid
nonsurvivor
group
compar
survivor
group
vs
p
tabl
addit
among
medic
administ
tabl
neutropaenia
significantli
associ
poor
outcom
among
infecti
caus
among
noninfecti
caus
p
vs
p
figur
show
overal
surviv
rate
patient
without
either
haematolog
hepat
dy
f
g
u
r
e
aetiolog
identif
diagnost
yield
noninvas
invas
test
perform
children
pi
hematopoiet
stem
cell
transplant
depict
noninvas
test
aetiolog
diagnosi
confirm
almost
half
episod
among
episod
neg
result
noninvas
test
invas
test
addit
perform
episod
show
higher
diagnost
yield
compar
noninvas
test
p
final
pi
aetiolog
identifi
especi
noninfecti
pc
overal
diagnost
yield
invas
test
studi
similar
increas
group
neg
result
noninvas
test
howev
major
episod
diagnos
use
noninvas
test
bal
lb
perform
total
episod
respect
nevertheless
mortal
rate
lower
present
studi
compar
previou
report
paediatr
recipi
manag
pc
critic
depend
possibl
presumpt
diagnosi
clinician
expect
identif
specif
aetiolog
would
allow
therapi
remov
chang
ad
would
lead
surviv
consist
previou
studi
found
modif
treatment
base
examin
result
perform
episod
influenc
outcom
contrast
yoo
et
al
report
affirm
effect
therapeut
modif
follow
procedur
diffus
pi
caus
respiratori
failur
cancer
patient
howev
studi
may
gener
hsct
patient
limit
special
icu
critic
ill
cancer
patient
furthermor
physician
decid
treatment
base
aetiolog
diagnos
also
respons
empir
treatment
clinic
experi
thu
difficult
find
direct
effect
aetiolog
diagnosi
treatment
modif
outcom
without
consider
medic
condit
howev
previous
mention
studi
pc
analys
comorbid
occur
major
recipi
follow
transplant
may
affect
treatment
choic
outcom
studi
extens
investig
predictor
outcom
inclus
comorbid
well
aetiolog
diagnosi
treatment
modif
although
studi
find
relationship
treatment
modif
outcom
target
therapi
accord
evalu
result
still
recommend
earli
deescal
antibiot
may
lead
posit
effect
includ
lower
level
multidrug
resist
bacteria
medic
toxic
organ
dysfunct
frequent
complic
hsct
recipi
whether
organ
dysfunct
result
highdos
condit
chemotherapi
transplantrel
insult
inflammatori
cytokin
tumour
necrosi
factoralpha
suggest
import
mediat
common
pathway
lead
organ
damag
may
toxic
effect
inflammatori
cytokin
vascular
endothelium
lead
proinflammatori
procoagul
state
tatma
high
mortal
rate
also
known
occur
result
vascular
endotheli
damag
studi
one
case
viral
pneumonia
coexist
tatma
die
mod
among
sever
organ
pulmonari
hepat
central
nervou
system
dysfunct
shown
similar
find
laboratori
test
low
anticoagul
protein
c
antithrombin
iii
clinic
outcom
subsequ
organ
dysfunct
death
multivari
analysi
organ
dysfunct
begin
pi
found
signific
prognost
factor
patient
pc
follow
hsct
recipi
pi
also
suffer
hepat
dysfunct
frequent
poor
outcom
half
patient
hepat
dysfunct
cooccur
vod
although
number
patient
small
evalu
outcom
accord
caus
hepat
dysfunct
could
presum
vod
common
caus
liver
dysfunct
might
relat
mortal
patient
pc
addit
whatev
caus
hepat
dysfunct
earli
stage
respiratori
distress
rather
advanc
stage
may
aggrav
respiratori
failur
organ
dysfunct
lead
poor
outcom
gordon
et
al
b
l
e
univari
analysi
mortal
factor
studi
therefor
studi
organ
dysfunct
treatment
need
improv
outcom
present
studi
sever
limit
first
studi
conduct
singl
centr
may
limit
generaliz
find
centr
close
discuss
among
experienc
oncologist
pulmonologist
intensivist
possibl
second
due
studi
retrospect
natur
select
bia
may
influenc
result
third
patient
group
small
draw
power
conclus
howev
present
studi
add
literatur
focus
import
comorbid
organ
dysfunct
often
neglect
studi
focus
diagnos
addit
adjust
multivari
analysi
serv
minim
potenti
select
bia
final
lack
result
pulmonari
function
test
hsct
limit
studi
howev
recipi
children
younger
year
old
lung
function
test
could
perform
routin
therefor
could
use
rel
factor
pc
conclus
hepat
dysfunct
neutropaenia
time
pi
initi
ascertain
independ
earli
predictor
mortal
although
addit
invas
diagnost
test
led
higher
diagnost
yield
aetiolog
diagnos
associ
treatment
modif
significantli
affect
mortal
howev
observ
need
evalu
multicentr
prospect
studi
variabl
show
signific
result
univari
analysi
p
note
tabl
includ
multivari
logist
regress
venoocclus
diseas
medic
administ
antibiot
antifung
agent
cytomegaloviru
treatment
hepat
dysfunct
neutropaenia
thrombocytopaenia
repres
haematolog
dysfunct
presenc
dysfunct
two
organ
final
three
variabl
found
static
signific
use
forward
stepwis
method
absolut
neutrophil
count
less
b
platelet
level
less
comparison
overal
surviv
rate
patient
pulmonari
complic
hematopoiet
stem
cell
transplant
accord
accompani
haematolog
andor
hepat
dysfunct
